Are there different strategies you would utilize to monitor and manage potential resistance in patients with CML receiving asciminib?

Overall, I use similar monitoring strategies for all CML therapies, including what responses or loss of response prompt me to consider assessment for mutations that confer therapy resistance. Sometimes it is difficult to differentiate non-adherence vs emerging resistance, and thus it is important to...

The monitoring is the same as we do for patients on any TKI. The unique aspect regarding mutations is that we mostly see mutations in the myristoyl pocket among patients with resistance to asciminib. I do not consider these harder to treat, as they would be sensitive in principle to conventional TKI...